Proteasome inhibitor delivered with cancer-killing viruses enhances effect

Researchers at The Ohio State University have found that to treat brain cancer and other solid tumors, a low dose of the proteasome inhibitor bortezomib improves oncolytic viruses' ability to kill cancer cells. According to the article published in the journal Clinical Cancer Research, bortezomib breaks down the structures in cancer cells that allow them to break down and recycle proteins, allowing the viruses a more fragile target. Report | Abstract